Latest Stock Advice
Signet Jewelers Ltd. is still subject to changes in consumer confidence, but it’s making smart moves to spur growth
Sun Life Financial Inc. and Manulife Financial Corp. each offers a combination of solid earnings growth, ongoing share repurchases, and impressive dividend yields.
Top pick Yum Brands Inc. gives you sales growth, steady EPS growth, and a solid dividend
Nutrien Ltd. offers exposure to potash and nitrogen prices, a stable retail base and strong profitability.
Become a Successful Investor
Tax shelters in Canada aim to reduce or eliminate your tax liability, they are great ways for Canadian investors to cut their tax bills.
In some ways, stock buyback benefits are better than dividends. In particular, they give you a tax-deferral option that you don’t get with cash dividends.
Broadridge Financial Solutions boosts earnings through acquisition and niche investment services.
IPO investing issues typically come to market when it’s a good time for the company or its insiders to sell. That’s often a bad time for you to buy
When the market is as volatile as it is today, it pays to keep the mechanics of successful investing in mind. For newcomers to our Inner Circle, let me start with a short explanation of our three-part Successful Investor approach to portfolio building: 1.Invest mainly in well-established, dividend-paying companies. Ideally, some of your picks should have hidden assets—that is, assets that many investors disregard or fail to appreciate....
Alnylam Pharmaceuticals, Inc., $73.82, symbol ALNY on Nasdaq (Shares outstanding: 84.7 million; Market cap: $6.5 billion; www.alnylam.com), develops drugs based on RNA interference (RNAi). Unlike traditional treatments, RNAi suppresses the expansion of specific genes associated with certain diseases. This process won a Nobel Prize in 2006, but no company has successfully launched a treatment using this technology. Recently, Alnylam reported positive clinical trial results for ALN-PCSsc, a treatment for high cholesterol. Alnylam and its partner, the Medicines Company, plan to begin Phase I trials in the next few weeks....